MedTrace Logo

MDPK67b in Patients With Prostate Cancer

NCT05580107 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-11-07

No results posted yet for this study

Summary

Administration of MDPK67b to assess its Tolerability and Safety profile in prostate cancer patients, and to assess histo-pathological and molecular changes in prostate tumor tissue samples.

Conditions

Interventions

DRUG

MDPK67b

24 mg or 48 mg

Sponsors & Collaborators

  • Camara and Partners Sàrl

    collaborator UNKNOWN

  • Soladis

    collaborator INDUSTRY

  • Med Discovery SA

    lead INDUSTRY

Principal Investigators

  • Daniel Eberli, Prof. · Klinik für Urologie, UniversitätSpital Zürich (USZ)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580107 on ClinicalTrials.gov